# Oxford Cancer (Oxford University Hospitals and University of Oxford)

Source: https://onco.cc/institutions/oxford-cancer/  
OnCo record `oxford-cancer` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Oxford's cancer partnership, combining the Churchill Hospital with the university's radiation oncology, Ludwig and early detection institutes and a deep drug and diagnostics spin-out tradition.

## Summary

Oxford Cancer unites the Oxford University Hospitals cancer and haematology services at the Churchill Hospital with the University of Oxford's Department of Oncology, the Oxford Institute for Radiation Oncology (descended from the Gray Laboratory's hypoxia research), the Ludwig Institute for Cancer Research Oxford branch and the Weatherall Institute of Molecular Medicine. The CRUK Oxford Centre and Oxford Centre for Early Cancer Detection focus on prevention, screening and liquid biopsy, while the Oxford Cancer and Haematology Centre runs early-phase and radiotherapy trials. Oxford science underpins companies such as Immunocore (from Avidex, whose tebentafusp became the first TCR bispecific approved for uveal melanoma) and Oxford Nanopore, and the ChAdOx vaccine platform is being tested for cancer vaccines. Patients access one of the UK's largest haematology and transplant programmes and a growing sarcoma and colorectal service.

## Fields

- Kind: Institution
- Last checked: 2026-09-09
- Also known as: Churchill Hospital Oxford Cancer and Haematology Centre; CRUK Oxford Centre; Oxford Institute for Radiation Oncology
- City: Oxford, GB
- Type: university
- Website: https://www.cancer.ox.ac.uk

## Sources

- Oxford Cancer: https://www.cancer.ox.ac.uk
- Department of Oncology: https://www.oncology.ox.ac.uk
- OUH cancer services: https://www.ouh.nhs.uk/cancer/

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Melanoma](https://onco.cc/cancers/melanoma/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/), [Radiation Therapy](https://onco.cc/fronts/radiation/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Off-the-shelf cancer vaccines](https://onco.cc/technologies/shared-antigen-vaccine/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/), [Whole-exome & whole-genome sequencing](https://onco.cc/technologies/wes-wgs/)
- targets: [gp100 (PMEL)](https://onco.cc/targets/gp100/)
- drugs: [Tebentafusp](https://onco.cc/drugs/tebentafusp/)
- companies: [Immunocore](https://onco.cc/companies/immunocore/)
- institutions: [Cancer Research UK](https://onco.cc/institutions/cruk/), [Thames Valley Cancer Alliance](https://onco.cc/institutions/thames-valley-cancer-alliance/)
- trials: [FOCUS4](https://onco.cc/trials/focus4/), [MRC COIN](https://onco.cc/trials/coin/), [Precision-Panc](https://onco.cc/trials/precision-panc/), [ProtecT](https://onco.cc/trials/protect/), [QUASAR](https://onco.cc/trials/quasar/), [SCOT](https://onco.cc/trials/scot/)
- people: [Freddie C. Hamdy](https://onco.cc/people/freddie-hamdy/), [Mark Middleton](https://onco.cc/people/mark-middleton/), [Rachel Kerr](https://onco.cc/people/rachel-kerr/), [Richard Gray](https://onco.cc/people/richard-gray/), [Sir Richard Peto](https://onco.cc/people/richard-peto/), [Tim Maughan](https://onco.cc/people/tim-maughan/)
- key papers: [Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study (QUASAR)](https://onco.cc/key-papers/paper-quasar-adjuvant-chemotherapy-vs-observation-lancet-2007/), [Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas](https://onco.cc/key-papers/paper-palles-germline-pole-pold1-proofreading-nat-genet-2013/), [Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer](https://onco.cc/key-papers/paper-domingo-somatic-pole-proofreading-colorectal-lancet-gastro-2016/)
- collections: [UK specialist HPB cancer centres](https://onco.cc/collections/uk-hpb-specialist-centres/)

---
JSON: https://onco.cc/api/v1/entities/oxford-cancer.json